Fructose effect on phosphate absorption from the gastrointestinal tract

The effect of fructose on hyperphosphatemia in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201307272017N15

Enrollment

Registered

2013-12-02

Start date

2013-10-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Failure. Chronic Kidney Failure

Interventions

Intervention group: 15 grams fructose daily for two months.

Treatment - Drugs

Intervention group: 15 grams fructose daily for two months

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: More than six months have passed from diagnosis of Chronic Renal Failure and to be at 4,5 stages of disease, >18 years old, Satisfaction and cooperation of patient, Constant consumption of fruit and fructose containing foods, Tolerance to drug and side effects.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Phosphate. Timepoint: Before and two months after the begining of trial. Method of measurement: Laboratory and mgr/dl.	—

Secondary

Measure	Time frame
Leucocytes. Timepoint: Before and two months after of beginning of trial. Method of measurement: Labratory and Numerical.;HDL. Timepoint: Before and two months after the beginning of trial. Method of measurement: Laboratory and mgr/dl.;Triglycerides. Timepoint: Before and two months after the beginning of trial. Method of measurement: Laboratory and mgr/dl.;Na. Timepoint: Before and two months after the beginning of trial. Method of measurement: Laboratory and mgr/dl.;Calcium. Timepoint: Before and two months after the beginning of trial. Method of measurement: Laboratory and mgr/dl.;K. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and mgr/dl.;PTH. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and by kit.;LDL. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and mgr/dl.;Cholesterol. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and mgr/dl.;Platelet. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and Numerical.;Hemoglobin. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and Numerical.	—

Measure

Time frame

Leucocytes. Timepoint: Before and two months after of beginning of trial. Method of measurement: Labratory and Numerical.;HDL. Timepoint: Before and two months after the beginning of trial. Method of measurement: Laboratory and mgr/dl.;Triglycerides. Timepoint: Before and two months after the beginning of trial. Method of measurement: Laboratory and mgr/dl.;Na. Timepoint: Before and two months after the beginning of trial. Method of measurement: Laboratory and mgr/dl.;Calcium. Timepoint: Before and two months after the beginning of trial. Method of measurement: Laboratory and mgr/dl.;K. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and mgr/dl.;PTH. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and by kit.;LDL. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and mgr/dl.;Cholesterol. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and mgr/dl.;Platelet. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and Numerical.;Hemoglobin. Timepoint: Before and after two months of beginning of trial. Method of measurement: Laboratory and Numerical.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Tayebikhosroshahi

Tabriz university of medical sciences

Drtayebikh@yahoo.com+98 914 315 8784

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026